We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.00 | -8.96% | 30.50 | 30.00 | 31.00 | 38.00 | 30.50 | 37.50 | 3,267,070 | 14:39:50 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -3.19M | -0.0469 | -6.50 | 20.76M |
TIDMSAR
RNS Number : 7737H
Sareum Holdings PLC
15 March 2018
(AIM: SAR) 15 March 2018
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum notes Sierra Oncology announcement that a late-breaking abstract reporting SRA737 preclinical activity in CCNE1-driven and PARP inhibitor-resistant cancers has been accepted for AACR 2018 Annual Meeting
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, announced that late-breaking preclinical results for SRA737 have been accepted for presentation in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2018 being held in Chicago, USA from 14-18 April. These data demonstrate that SRA737 has anti-tumour activity as a monotherapy in both CCNE1-driven cancer models and in cancer models resistant to poly ADP-ribose (PARP) inhibitor therapy, thereby warranting further investigation in human clinical studies.
Sierra Oncology recently announced that its ongoing Phase 1/2 monotherapy trial for SRA737 was being expanded to include an additional genetically-defined cohort, targeting enrolment of 20 patients with CCNE1-driven ovarian cancer. Approximately 20% of high grade serous ovarian cancers have an amplification of the CCNE1 gene, which is also prevalent across several other tumour types under evaluation in Sierra Oncology's ongoing clinical development programme, including non-small cell lung, colorectal, bladder and cervical cancer.
Sierra Oncology also recently announced it was planning to start a Phase 1b/2 combination trial in the UK of SRA737 with the PARP inhibitor niraparib in patients with prostate cancer, expected in the fourth quarter of 2018.
The full announcement from Sierra Oncology can be found at www.sierraoncology.com
Details of the Poster
Poster Title: The novel oral Chk1 inhibitor, SRA737, is active in both PARP inhibitor resistant and CCNE1 amplified high grade serous ovarian cancers
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date and Time: Tuesday, April 17, 2018 from 1:00 PM - 5:00 PM Central Time.
Location: Poster Section 43
Poster Board Number: 9
Permanent Abstract Number: LB-265
The Poster will be available 17 April 2018 at www.sierraoncology.com.
For further information, please contact:
Sareum Holdings plc Tim Mitchell 01223 497 700 WH Ireland Limited (Nominated Adviser and Co-Broker) Chris Fielding / James Sinclair-Ford 020 7220 1666 Hybridan LLP (Co-Broker) Claire Noyce 020 3764 2341 Citigate Dewe Rogerson (Media enquiries) Shabnam Bashir/ Mark Swallow/ David Dible 020 7282 9571
Notes for editors:
About Sareum
Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in Phase 1/2 clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted monotherapy and in combination with other oncology and immuno-oncology drugs in genetically defined patients.
Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the candidate selection and IND-enabling preclinical stages.
The Company's drug discovery technology platform (SKIL(R) - Sareum Kinase Inhibitor Library) has the potential to generate drug research programmes against other kinase targets.
Sareum Holdings plc is quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk.
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESEAADLFDXPEAF
(END) Dow Jones Newswires
March 15, 2018 03:01 ET (07:01 GMT)
1 Year Sareum Chart |
1 Month Sareum Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions